Y0001511
格列本脲
European Pharmacopoeia (EP) Reference Standard
别名:
5-氯-N-[4-(环己基脲磺酰)苯乙基]-2-甲氧基苯甲酰胺, N-对[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰基-N′-环己基脲, 格列本脲
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C23H28ClN3O5S
CAS Number:
分子量:
494.00
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
glibenclamide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI
1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
InChI key
ZNNLBTZKUZBEKO-UHFFFAOYSA-N
基因信息
human ... ABCC8(6833), KCNJ11(3767)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Glibenclamide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
危险声明
预防措施声明
危险分类
Aquatic Chronic 4
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
J F Caro
The American journal of medicine, 89(2A), 17S-25S (1990-08-20)
Increased hepatic glucose production is responsible for fasting hyperglycemia in type II diabetes. Insulin resistance is the key in this process because of the inability of insulin to suppress hepatic glucose production, thereby allowing an unopposed glucagon effect. Glyburide, one
Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature.
J P van Basten et al.
The Netherlands journal of medicine, 40(5-6), 305-307 (1992-06-01)
As sulphonylurea derivatives are used ubiquitously, the possibility that they may cause liver disease deserves attention. In contrast to the known pattern of reversible parenchymal liver disease due to sulphonylurea derivatives, we describe a fatal case of glyburide-induced cholestatic hepatitis
Faiyaz Shakeel et al.
Pharmaceutical development and technology, 19(6), 702-707 (2013-08-13)
Temperature-dependent solubility data of glibenclamide (GBN) in various ethanol-water mixtures is not reported in literature so far. Therefore, the aim of this study was to determine the mole fraction solubility of GBN in various ethanol-water mixtures at the temperature range
J M Feldman
The American journal of medicine, 79(3B), 102-108 (1985-09-20)
After one year on the American market, glyburide, a second-generation sulfonylurea, seems well accepted by physicians. If the hyperglycemia of patients with type II diabetes mellitus is not corrected by diet and exercise, glyburide can be used as adjunctive therapy.
N M O'Meara et al.
The American journal of medicine, 89(2A), 11S-16S (1990-08-20)
Since the introduction of glyburide in 1984, many studies have evaluated the effects of this oral hypoglycemic agent on beta cell function in patients with non-insulin-dependent diabetes mellitus. The early studies, which were performed in patients receiving concomitant insulin therapy
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持